Inicio › Enfermedad de Crohn › Texas › Tyler
Ensayos clínicos de Enfermedad de Crohn en Tyler, TX
16 estudios para Enfermedad de Crohn buscan participantes en centros de Tyler y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
ReclutandoFase 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
ReclutandoFase 3
- Tyler Research Institute ( Site 5001), Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
ReclutandoFase 3
- Tyler Research Institute, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
ReclutandoFase 2
- Tyler Research Institute, LLC, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
ReclutandoFase 2/3
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
ReclutandoFase 3
- Tyler Research Institute, LLC, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
ReclutandoFase 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
ReclutandoFase 2
- Tyler Research Institute, LLC, Tyler
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
ReclutandoFase 2
- Tyler Research Institute /ID# 284247, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
ReclutandoFase 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
ReclutandoFase 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
ReclutandoFase 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
ReclutandoFase 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
ReclutandoFase 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
ReclutandoFase 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
ReclutandoFase 2
- Mirador Therapeutics Selected Site, Tyler
Más información sobre Enfermedad de Crohn en MedlinePlus
Ensayos de Enfermedad de Crohn en otras ciudades
- New York City, NY33 estudios
- St. Louis, MO19 estudios
- Miami, FL19 estudios
- Orlando, FL19 estudios
- Boston, MA18 estudios
- Houston, TX17 estudios
- Atlanta, GA16 estudios
- San Diego, CA15 estudios
- Cleveland, OH15 estudios
- Colorado Springs, CO14 estudios
- San Antonio, TX14 estudios
- Los Angeles, CA13 estudios
Otros estudios en Tyler
- Cáncer de pulmón de células no pequeñas19 estudios
- Colitis ulcerativa13 estudios
- Cáncer de ovario9 estudios
- Cáncer del colon y del recto8 estudios
- Fallo cardíaco8 estudios
- Cáncer (todos los tipos)7 estudios
- Carcinoma de células escamosas de cabeza y cuello6 estudios
- Cáncer de endometrio6 estudios
- Fibrilación auricular6 estudios
- Cáncer de seno5 estudios
- Cáncer metastásico5 estudios
- Cáncer de pulmón de células pequeñas5 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.